1,000-Patient study to see if ancient herbal medicine slows lung scarring

NCT ID NCT07162870

Not yet recruiting Knowledge-focused Sponsor: Henan University of Traditional Chinese Medicine Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will follow 1,000 people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and breathing problems. Researchers will compare those who take traditional Chinese medicine (TCM) for at least three months a year to those who do not. The goal is to see if TCM reduces flare-ups and slows disease progression, and to identify which patients benefit most.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Traditional Chinese medicine (herbal formulas taken for at least 3 months per year)
What this could lead to: If successful, this study could help doctors identify which IPF patients are most likely to benefit from traditional Chinese medicine, and guide more personalized treatment decisions.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Differences between groups may be due to other factors, and results may not apply to all IPF patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC PULMONARY FIBROSIS (IPF)

Contacts and locations

Locations

The First Affiliated Hospital of Henan University of Chinese Medicine

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.